<DOC>
	<DOCNO>NCT00397566</DOCNO>
	<brief_summary>The purpose clinical research study ass safety , pharmacokinetics pharmacodynamics BMS-707035 subject infect HIV-1</brief_summary>
	<brief_title>A Multiple Ascending Dose Study BMS-707035 HIV-1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<mesh_term>HIV Integrase Inhibitors</mesh_term>
	<criteria>HIV1infected subject CD4+ lymphocyte count ≥ 200 cells/mm3 plasma HIV1 RNA ≥ 5000 copies/mL antiretroviral ( ARV ) therapy ≥ 8 week naive ARV , otherwise medically stable determined medical history , physical examination , 12 lead electrocardiogram , clinical laboratory evaluation eligible participate study . In addition , subject must prior exposure Integrase Inhibitor class compound . Female subject must nurse , pregnant , childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>